Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Mamidi, Murali K ^a,b   Singh, Gurbind ^a   Husin, Juani M ^a   Nathan, Kavitha G ^a   Sasidharan, Gopinath ^a   Zakaria, Zubaidah ^c   Bhonde, Ramesh ^b   Majumdar, Anish S ^d   Das, Anjan K ^a  

^a Stempeutics Research Malaysia Sdn Bhd   (Malaysia)

^b Manipal Academy of Higher Education   (India)

^c INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^d Akshay Tech Park   (India)

Author keywords

Bone Marrow Mesenchymal stem cells (BM MSC); Cell migration needle bore size; Differentiation; MSC transplantation infusion

Indexed keywords

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL MIGRATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSFER; CELL VIABILITY; CLINICAL PRACTICE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOLOGY; ESTHETIC SURGERY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VIVO STUDY; MESENCHYMAL STEM CELL; NEEDLE; PATIENT SAFETY; PHENOTYPE; PLASTICITY; SMALL BORE SIZE NEEDLE; SYRINGE; TISSUE SECTION;

ADULT; ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CARBOCYANINES; CELL ADHESION; CELL AGING; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MOVEMENT; CELL SHAPE; CELL SURVIVAL; COSMETICS; CRYOPRESERVATION; HUMANS; INJECTIONS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEEDLES; PHENOTYPE; RATS; RATS, NUDE; STAINING AND LABELING; YOUNG ADULT;

EID: 84869211832     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-229     Document Type: Article

References (33)

1. Agashi K, Chau DY, Shakesheff KM. The effect of delivery via narrow-bore needles on mesenchymal cells. Regen Med 2009, 4(1):49-64. 10.2217/17460751.4.1.49, 19105616.
2. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 2010, 3(4):248-269. 2971538, 21072260.
3. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissue. Transplantation 1968, 6:230-234. 10.1097/00007890-196803000-00009, 5654088.
4. Gala K, Burdzińska A, Idziak M, Makula J, Pa{ogonek}czek L. Characterization of bone marrow derived rat mesenchymal stem cells depending on donor age. Cell Biol Int 2011, 35(10):1055-1062. 10.1042/CBI20100586, 21592091.
5. Mamidi MK, Pal R, Mori NA, Arumugam G, Thrichelvam ST, Noor PJ, Abdullah HM, Gupta PK, Das AK, Zakaria Z, Bhonde R. Co-culture of mesenchymal-like stromal cells derived from human foreskin permits long term propagation and differentiation of human embryonic stem cells. J Cell Biochem 2011, 112(5):1353-1363. 10.1002/jcb.23052, 21337383.
6. Montanucci P, Basta G, Pescara T, Pennoni I, Di Giovanni F, Calafiore R. New simple and rapid method for purification of mesenchymal stem cells from the human umbilical cord Wharton jelly. Tissue Eng Part A 2011, 17(21-22):2651-2661.
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4):315-317. 10.1080/14653240600855905, 16923606.
8. Herrero H, Perez-Simon JA. Immunomodulatory effect of mesenchymal stem cells. Braz J Med Biol Res 2010, 43(5):425-430. 10.1590/S0100-879X2010007500033, 20490429.
9. Waterman R, Betancourt A. Outside the operating room: unlimited directions in research and beyond. Ochsner J 2011, 11(1):14-16. 3096162, 21603329.
10. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67(10):1187-1194. 10.1001/archneurol.2010.248, 3036569, 20937945.
11. Perl L, Weissler A, Mekori YA, Mor A. Cellular therapy in 2010: focus on autoimmune and cardiac diseases. Isr Med Assoc J 2010, 12(2):110-115.
12. Ringe J, Sittinger M. Tissue engineering in the rheumatic diseases. Arthritis Res Ther 2009, 11(1):211. 10.1186/ar2572, 2688224, 19232063.
13. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009, 183(2):993-1004. 10.4049/jimmunol.0900803, 19561093.
14. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kötter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R. Autologous hematopoitic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for blood and marrow transplantation working party on autoimmune diseases. Haematolica 2010, 95(2):284-292.
15. Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoitic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl) 2006, 119(22):1851-1855.
16. Schwab IR, Reyes M, Isseroff RR. Succesful transplantation of bioengineered tissue replacements in patients with ocular surface disease. Am J Ophthalmol 2000, 130(4):543-544.
17. Vassalli G, Moccetti T. Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Med Wkly 2011, 141:w13209. 10.4414/smw, 21607881.
18. Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data. Exp Clin Transplant 2009, 7(4):241-248.
19. Center for Biologics Evaluation and Research, C. B. E. R Guidance for Industry. Potency tests for cellular and gene therapy products 2008, Center for Biologics Evaluation and Research, C. B. E. R.
20. Tol M, Akar AR, Durdu S, Ayyildiz E, Ilhan O. Comparison of different needle diameters and flow rates on bone marrow mononuclear stem cell viability: an ex vivo experimental study. Cytotherapy 2008, 10(1):98-99. 10.1080/14653240701762356, 18202979.
21. Pal R, Hanwate M, Totey SM. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation. J Tissue Eng Regen Med 2008, 2(7):436-444. 10.1002/term.109, 18720444.
22. Nekanti U, Dastidar S, Venugopal P, Totey S, Ta M. Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia. Int J Biol Sci 2010, 6(5):499-512. 2945278, 20877435.
23. Majore I, Moretti P, Hass R, Kasper C. Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord. Cell Commun Signal 2009, 7:6. 10.1186/1478-811X-7-6, 2676292, 19302702.
24. Perin EC, Lopez J. Methods of stem cell delivery in cardiac diseases. Nat Clin Pract Cardiovasc Med 2006, 1:10-13.
25. Kondziolka D, Steinberg GK, Cullen SB, McGrogan M. Evaluation of surgical techniques for neuronal cell transplantation used in patients with stroke. Cell Transplant 2004, 13(7-8):749-754.
26. Heng BC, Hsu SH, Cowan CM, Liu A, Tai J, Chan Y, Sherman W, Basu S. Transcatheter injection-induced changes in human bone marrow-derived mesenchymal stem cells. Cell Transplant 2009, 18(10):1111-1121. 10.3727/096368909X12483162197006, 19650972.
27. Mamidi MK, Nathan KG, Singh G, Thrichelvam ST, Mohd Yusof NA, Fakharuzi NA, Zakaria Z, Bhonde R, Das AK, Majumdar AS. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem 2012, 113(10):3153-3164. 10.1002/jcb.24193, 22615164.
28. Naaldjik Y, Staude M, Federova V, Stolzing A. Effect of different freezing rates during cryopreservation of rat mesenchymal stem cells using combinations of hydroxyethyl starch and dimethylsulfoxide. BMC Biotechnol 2012, 12(1):49. 10.1186/1472-6750-12-49, 3465236, 22889198.
29. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA, Kessler J. Clinical applications of blood-derived and marrow derived stem cells for nonmalignant diseases. JAMA 2008, 299(8):925-936. 10.1001/jama.299.8.925, 18314435.
30. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci 2004, 117(Pt 23):5655-5664.
31. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, Wu JC, Chen X. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 2009, 27(7):1548-1558. 10.1002/stem.81, 19544460.
32. Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI. Defining human mesenchymal stem cell efficacy in vivo. J Inflamm (Lond) 2010, 7:51.
33. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008, 14(2):181-187. 10.1038/nm1703, 18193058.